ARWR
Arrowhead Pharmaceuticals Inc
NASDAQ: ARWR · HEALTHCARE · BIOTECHNOLOGY
$70.53
+0.57% today
Updated 2026-04-29
Market cap
$9.88B
P/E ratio
44.08
P/S ratio
9.05x
EPS (TTM)
$1.60
Dividend yield
—
52W range
$12 – $77
Volume
2.2M
Arrowhead Pharmaceuticals Inc (ARWR) Earnings
Quarterly earnings history, analyst estimates, and stock price reaction.
EPS beat streak
3 of 8
Last 8 quarters
Avg EPS surprise
+77.4%
Last 4 quarters
Revenue YoY growth
+10461.3%
Most recent quarter
EPS YoY growth
+115.8%
Most recent quarter
Earnings surprise history (last 12 quarters)
Beat estimate Missed estimate
Quarterly EPS and revenue trend
Quarterly revenue EPS (diluted)
How the stock reacts to earnings
Avg 1-day reaction
+9.8%
Last 3 reports
Positive reaction rate
67%
2 of 3 quarters
Largest single-day move
+30.4%
2025-11-25
| Report date | EPS actual | Surprise | Close before | Close after | 1-day reaction |
|---|---|---|---|---|---|
| 2026-02-10 | $0.22 | +91.5% | $62.64 | $61.55 | -1.7% |
| 2025-11-25 | $-0.11 | +64.5% | $44.26 | $57.71 | +30.4% |
| 2025-08-07 | $-1.26 | -46.5% | $16.31 | $16.42 | +0.7% |
Quarterly earnings history
| Fiscal quarter ending | EPS estimate | EPS actual | Surprise | Revenue | YoY revenue |
|---|---|---|---|---|---|
| 2025-12-31 | $0.11 | $0.22 | +91.5% | $264.03M | +10461.3% |
| 2025-09-30 | $-0.31 | $-0.11 | +64.5% | $256.47M | +987.3% |
| 2025-06-30 | $-0.86 | $-1.26 | -46.5% | $27.77M | — |
| 2025-03-31 | $-0.46 | $2.75 | +695.0% | $542.71M | — |
| 2024-12-31 | $-0.72 | $-1.39 | -92.1% | $2.50M | -29.6% |
| 2024-09-30 | $-0.92 | $-1.37 | -48.6% | $23.59M | +46.5% |
| 2024-06-30 | $-0.55 | $-1.38 | -150.9% | — | — |
| 2024-03-31 | $-0.16 | $-1.02 | -537.5% | — | — |
| 2023-12-31 | $-0.82 | $-1.24 | -51.2% | $3.55M | — |
| 2023-09-30 | $-0.60 | $-1.02 | -70.0% | $16.10M | — |
| 2023-06-30 | $-0.65 | $-0.96 | -47.7% | $15.82M | — |
| 2023-03-31 | $-0.64 | $0.45 | +170.3% | $146.27M | — |
Frequently asked questions
Has Arrowhead Pharmaceuticals Inc beaten earnings estimates?
Arrowhead Pharmaceuticals Inc has beaten Wall Street EPS estimates in 3 of its last 8 quarterly reports, with an average EPS surprise of +77.4% over the last 4 quarters.
How does ARWR stock react to earnings?
ARWR stock has moved an average of +9.8% in the trading day following earnings over its last 3 reports, with positive reactions in 67% of those quarters.
What is Arrowhead Pharmaceuticals Inc's revenue growth rate?
Arrowhead Pharmaceuticals Inc reported year-over-year revenue growth of +10461.3% in its most recent quarter, with EPS growing +115.8% year-over-year.